Habitat Suitability Modeling to Identify the Potential Nursery Grounds of the Atlantic Mackerel and Its Relation to Oceanographic Conditions in the Mediterranean Sea

Our knowledge for the distribution of Atlantic mackerel (Scomber scombrus) in the Mediterranean Sea is limited and fragmented. In the current work habitat suitability modeling was applied to summer acoustic surveys data of Atlantic mackerel juveniles derived from the north part of the Mediterranean (i.e., acoustic data from the Gulf of Lions, pelagic trawls held during acoustic surveys in Spanish Mediterranean waters, south Adriatic Sea, Strait of Sicily, and North Aegean Sea) using generalized additive models (GAMs) along with satellite environmental and bathymetry data. Bathymetry along with sea surface temperature and circulation patterns, expressed through sea level anomaly and the zonal component of the absolute geostrophic velocity, were the environmental variables best to describe nursery grounds. The selected model was used to produce maps presenting the potential nursery grounds of Atlantic mackerel throughout the Mediterranean Sea as a measure of habitat adequacy. However, the assessed potential nursery grounds were generally marked as “occasional,” implying that although there are areas presenting high probability to encounter Atlantic mackerel, this picture can largely vary from year to year stressing the high susceptibility of the species to environmental conditions. In a further step and toward a spatial management perspective, we have estimated and visualized the overlap between Atlantic mackerel and anchovy/ sardine juvenile grounds throughout the basin. Results showed that although the degree of overlapping was generally low, not exceeding 15% in general, this varied at a regional level going up to 30%. The potential of the output of this work for management purposes like the implementation of spatially-explicit management tools is discussedVersión del edito

Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study.

There are few effective, safe modalities for the management of Graves' ophthalmopathy (GO), a cell-mediated immune comorbidity of thyroid disease. Somatostatin analogs inhibit lymphocyte proliferation and activation, and accumulate in the orbital tissue of patients with GO. A double-blind, placebo-controlled study of a long-acting somatostatin analog [16 wk of long-acting release formulation of octreotide (octreotide-LAR)] was conducted in 51 patients with mild active GO with the aim of preventing deterioration and precluding the need for more aggressive therapeutic modalities, such as glucocorticoids or radiotherapy. No treatment effect was observed for the primary end point (a composite parameter defining the outcome as either success or failure on the basis of changes in class/grade of the severity index and Clinical Activity Scale of GO). The Clinical Activity Scale score was reduced for patients treated with octreotide-LAR, but without any significant difference with respect to patients receiving placebo. However, octreotide-LAR significantly reduced proptosis (as measured by exophthalmometry). This was associated with nonsignificant differences in favor of octreotide-LAR in a series of proptosis-related parameters: class III grade, opening of the upper eyelid, the difference in ocular pressure between primary position and upgaze, and extraocular muscle involvement. By magnetic resonance imaging evaluation the extraocular muscle volumes appeared reduced, but nonsignificantly. No significant correlation between the initial uptake of the somatostatin analog indium-labeled and the response to treatment was observed. One patient in the octreotide-LAR group developed gallstones. In this study, octreotide-LAR did not seem suitable to mitigate activity in mild GO. Surprisingly, it significantly reduced proptosis, one of the most debilitating symptoms of GO. Additional studies are warranted to define the benefit to risk ratio of the somatostatin analogs in this indication